APA (7th ed.) Citation

M, A., J, H., L, A., MG, G., E, B., G, G., . . . L, B. (2026). Papillary renal cell carcinoma - exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological review. European journal of cancer (Oxford, England : 1990), 243, 116816. https://doi.org/10.1016/j.ejca.2026.116816

Chicago Style (17th ed.) Citation

M, Ahrens, et al. "Papillary Renal Cell Carcinoma - Exploratory Results of the SUNNIFORECAST Trial Comparing Ipilimumab Plus Nivolumab Vs Standard of Care as First Line Therapy Based on Central Pathological Review." European Journal of Cancer (Oxford, England : 1990) 243 (2026): 116816. https://doi.org/10.1016/j.ejca.2026.116816.

MLA (9th ed.) Citation

M, Ahrens, et al. "Papillary Renal Cell Carcinoma - Exploratory Results of the SUNNIFORECAST Trial Comparing Ipilimumab Plus Nivolumab Vs Standard of Care as First Line Therapy Based on Central Pathological Review." European Journal of Cancer (Oxford, England : 1990), vol. 243, 2026, p. 116816, https://doi.org/10.1016/j.ejca.2026.116816.